Lih Hwa Hwang

Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion.

T cell proliferative responses to hepatitis B virus-encoded envelope antigen (S + preS2 + preS1), recombinant core antigen (HBcAg), and natural hepatitis B e antigen (HBeAg) were examined in 22 HBeAg-positive patients with chronic type B hepatitis and 17 healthy hepatitis B surface antigen (HBsAg) carriers. The results showed that HBeAg-positive patients had (a) higher levels of T cell responses to HBcAg/HBeAg than those of healthy HBsAg carriers (P less than 0.001 and P less than 0.01, respectively); (b) a further increase in these T cell responses during acute exacerbations (P less than 0.05 and P less than 0.05, respectively); (c) subsidence in the T cell responses to HBcAg/HBeAg after recovery from acute exacerbations and HBeAg seroconversion, whereas the responses would persist at high levels if the patients did not enter a clinical remission; and (d) low levels of T cell responses to S + preS2 + preS1 either before or after HBeAg seroconversion. The appearance of increasing T cell responses to HBcAg/HBeAg usually occurred in the early phase of acute exacerbations. These findings imply that HBcAg/HBeAg-specific T cells play an important role in the exacerbations of chronic hepatitis B and in HBeAg seroconversion. HBcAg/HBeAg-specific precursor T cell frequencies were serially studied in selected cases by limiting dilution assay. Elevation (two- to fourfold) of HBcAg/HBeAg-specific precursor T cell frequencies contributed to the increase of HBcAg/HBeAg-specific T cell proliferation during acute exacerbations.

Tumor-induced immunosuppression : A barrier to immunotherapy of large tumors by cytokine-secreting tumor vaccine

An active immunotherapy strategy with cytokine-assisted tumor vaccine, although often effective for small tumor burdens, is much less so for large tumor burdens. This study examines how large tumors might suppress the T cell functions and escape from the immune responses elicited by a granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vaccine. According to our results, the T cells isolated from the tumor-bearing mice treated late with the vaccine failed to confer protective activity on naive mice against a wild-type tumor challenge, unlike those isolated from the early-treated group. Nevertheless, the antitumor activity of the inactive T cells could be restored on in vitro stimulation. Expression of transforming growth factor beta (TGF-beta) and interleukin 10 (IL-10), the potent immunosuppressive factors, was detected in the parental tumor cell line RLmale 1 (a murine T leukemia cell line), as well as in the tumor region, the levels of which correlated with tumor progression. An in vitro assay of T cell functions revealed that the TGF-beta in the conditioned medium of RLmale 1 cells mainly affected the activation, whereas the IL-1male affected the activation to a lesser extent, but significantly affected the cytolytic activity, of tumor-specific T cells. The immunosuppressive activity of IL-10 was also signified by the findings that administration of the conditioned medium of RLmale 1 cultured in a serum-free medium, in which the TGF-beta activity was then lost while the IL-10 activity still remained, or of recombinant IL-10 to the early-treated group of mice abrogated the known efficacy of tumor vaccine on the small tumors. These data suggested that the efficacy of cytokine-secreting tumor vaccine was blocked by the immunosuppressive factors secreted from the large tumors. The results have important implications for the clinical design of immunotherapeutic strategies for advanced cancer patients.

Prominent proliferative response of peripheral blood mononuclear cells to a recombinant non‐structural (NS3) protein of hepatitis C virus in patients with chronic hepatitis C

The proliferative response of peripheral blood mononuclear cells (PBMC) to a recombinant non‐structural (NS3) protein of hepatitis C virus (HCV) was studied in 41 patients with chronic hepatitis C. Of them, 28 had chronic persistent hepatitis (CPH) and 13 chronic active hepatitis (CAH). The positive proliferation rate of PBMC to the recombinant NS3 protein, T9Ag, was 66% in the 41 patients (77% in CAH versus 61 % in CPH; P > 0·05) when stimulation index (SI) = 4 was set as the cut‐off value. However, mean SI of CAH patients was significantly higher than that of CPH patients (8·3 ± 5·2 versus 5·1 ± 3·6; P < 0·05). Six other chronic hepatitis patients who were repeatedly negative for anti‐HCV antibody but positive for serum HCV RNA also had an SI of ≥ 4·0. The frequency of cellular immune response to the T9Ag is among the highest results obtained by using HCV antigens tested so far. Our studies thus indicate that NS3 is an immunologically important region of HCV for T cells. Moreover, the proliferative response to T9Ag may help to establish hepatitis C etiology in chronic hepatitis patients who are seronegative with currently available anti‐HCV assays.

Improved gene expression by a U3-based retroviral vector

To improve the expression of the genes transduced by retroviral vectors, we have constructed a U3-based retroviral vector and evaluated its effect on the expression of an insert from the internal promoter. The unique feature of the vector is that the transduced gene is inserted at the U3 region of the 3 long terminal repeats (LTR). Consequently, in the infected cells the gene is duplicated and transferred to the 5-LTR. When compared with the conventional retroviral vectors which insert the gene within the retroviral transcriptional unit, the U3-based vectors greatly enhanced the expression of the transduced gene under all three promoters tested, viz. the cytomegalovirus immediately early gene promoter (CMV), the SV40 early gene promoter (SV), and the herpes simplex virus thymidine kinase gene promoter (TK). The SV and TK promoters which were previously shown suppressed by the retroviral promoter in the conventional construction restored their potencies in the U3-based vectors. Our results therefore suggested that the U3-based vectors are more advantageous than the conventional vectors for gene expression.

T-cell antigenic determinants within hepatitis C virus nonstructural protein 3 and cytokine production profiles in hepatitis C.

summary.u2002The aim of this study was to further investigate the role of T‐helper cells in hepatitis C virus (HCV) infection, focusing on the T‐cell antigenic determinants and cytokine profiles of nonstructural 3 (NS3) protein‐stimulated peripheral blood mononuclear cells (PBMCs) of HCV patients. A total of 12 recombinant proteins of theNS3 region were purified and used to test T‐cell proliferative response and antigenic determinants of HCV‐seropositive patients. In addition, cytokines produced by antigen stimulated PBMCs were measured. Our data showed that PBMCs from 55.7% (34/61) of HCV patients proliferated to at least one antigen, but PBMCs of HCV seronegative patients did not. In addition, PBMCs from about 82.0% (32/39) HCV‐seropositive patients produced significant amounts of cytokines (10u2003pg/mL). Interestingly, PBMCs from 66% of patients produced TH2‐related cytokines such as interleukin (IL)‐4 and IL‐5. In mappingexperiments, the data showed multiple T‐cell antigenic determinants. Our data demonstrated that NS3 antigen‐stimulated PBMCs of HCV patients recognized multiple T‐cell antigenic determinants and produced significant amounts of TH0 or TH2‐related cytokines, which might play a critical role in the chronicity of HCV infection.